|
Financial Information Relating to Reportable Segments (Detail) (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Mar. 31, 2014
|
Mar. 31, 2013
|
Mar. 31, 2014
|
Mar. 31, 2013
|
|
| Segment Reporting Information [Line Items] | ||||
| External sales | $ 95,555 | $ 80,992 | $ 265,240 | $ 231,100 |
| Earnings before income taxes | 46,069 | 44,466 | 121,941 | 119,898 |
|
Reportable Segment
|
||||
| Segment Reporting Information [Line Items] | ||||
| External sales | 95,555 | 80,992 | 265,240 | 231,100 |
| Earnings before income taxes | 47,750 | 45,493 | 127,814 | 123,621 |
|
Reportable Segment | Biotechnology
|
||||
| Segment Reporting Information [Line Items] | ||||
| External sales | 80,134 | 75,285 | 223,881 | 214,416 |
| Earnings before income taxes | 44,593 | 43,246 | 120,589 | 117,123 |
|
Reportable Segment | Clinical Controls
|
||||
| Segment Reporting Information [Line Items] | ||||
| External sales | 15,421 | 5,707 | 41,359 | 16,684 |
| Earnings before income taxes | 3,157 | 2,247 | 7,225 | 6,498 |
|
Unallocated Amount to Segment
|
||||
| Segment Reporting Information [Line Items] | ||||
| Earnings before income taxes | $ (1,681) | $ (1,027) | $ (5,873) | $ (3,723) |